Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF649 antisense RNA 1 (ZNF649-AS1)
- Target
- ZNF649-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
ZNF649 antisense RNA 1 (ZNF649-AS1) is a long non-coding RNA found on chromosome 19 that acts as an antisense transcript relative to the ZNF649 gene. It is upregulated in trastuzumab-resistant breast cancer cells and tissues, and its high expression is associated with poor response and shorter survival in patients receiving trastuzumab therapy. Functionally, ZNF649-AS1 promotes autophagy and suppresses apoptosis by recruiting the RNA binding protein PTBP1, which enhances the transcription of ATG5, an autophagy-related gene. Inhibition of ZNF649-AS1 can reverse trastuzumab resistance and sensitize cancer cells to therapy, making it a potential therapeutic target and biomarker for monitoring treatment efficacy in HER2-positive breast cancer patients. Its precise biological roles are still being elucidated, but it is implicated in the post-transcriptional regulation of cell survival and drug response pathways.
- Other names
- ZNF649-AS1
02
Mechanism of action
Not directly drug-targeted, but silencing ZNF649-AS1 sensitizes cells to trastuzumab by inhibiting autophagy through downregulation of ATG5
03
Biological functions
Regulation of autophagyModulation of drug resistanceRegulation of apoptosisPost-transcriptional gene regulation
04
Disease associations
CancerDrug resistance (specifically trastuzumab resistance in breast cancer)Other (potential involvement in cellular stress responses)
05
Safety considerations
Potential for promoting resistance to cancer therapiesNo established therapeutic interventions targeting ZNF649-AS1 in clinical use, so safety is hypothetical
06
Interacting drugs
07
Biomarkers
ZNF649-AS1 expression in serum as a predictive biomarker for trastuzumab response and prognosis in breast cancer
Beyond the preview
Go deeper on ZNF649 antisense RNA 1 (ZNF649-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZNF649 antisense RNA 1 (ZNF649-AS1).